Spectrum Medical, Inc. — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$49,793	10
2024	Research	$135,890	15
2023	Research	$2,215	2
2022	Research	$29,867	9
2021	Research	$30,633	10
2020	Research	$7,161	2
2019	Research	$10,656	4

Breakdown

Who paid Research payments · program years 2019–2025

Arthrex, Inc. $187,898 27 payments
Anika Therapeutics, Inc. $67,661 21 payments
Ironwood Pharmaceuticals, Inc $10,656 4 payments

Studies the money was for Research payments · program years 2019–2025

ACP Max (AICS/600) $185,683 25 payments
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee $60,500 19 payments
Rdea594-401 $10,656 4 payments
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee $6,000 1 payment
ACP Max (AICS/600) $2,215 2 payments
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee $1,161 1 payment

What the money was spent on Research payments · program years 2019–2025

Overhead $128,487 13 payments
Patient care $7,403 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.